{"id":"https://openalex.org/W2893629193","doi":"https://doi.org/10.1200/jco.2018.36.30_suppl.326","title":"A data driven approach to immunotherapy toxicity management.","display_name":"A data driven approach to immunotherapy toxicity management.","publication_year":2018,"publication_date":"2018-09-25","ids":{"openalex":"https://openalex.org/W2893629193","doi":"https://doi.org/10.1200/jco.2018.36.30_suppl.326","mag":"2893629193"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.30_suppl.326","doi":"https://doi.org/10.1200/jco.2018.36.30_suppl.326","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.30_suppl.326","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108140545","display_name":"Sadiqa Mahmood","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sadiqa Mahmood","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050997657","display_name":"Eli Schwamm","orcid":"https://orcid.org/0000-0001-6079-8796","observed_orcids":["https://orcid.org/0000-0001-6079-8796"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eli Schwamm","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063009872","display_name":"Kenneth L. Kehl","orcid":"https://orcid.org/0000-0001-5339-9797","observed_orcids":["https://orcid.org/0000-0001-5339-9797"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenneth L. Kehl","raw_affiliation_strings":["Dana 1115-B, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana 1115-B, Boston, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060510354","display_name":"Brett E. Glotzbecker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brett Glotzbecker","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Robert Andrews","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Andrews","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084134561","display_name":"Prabhsimranjot Singh","orcid":"https://orcid.org/0000-0001-6791-5123","observed_orcids":["https://orcid.org/0000-0001-6791-5123"]},"institutions":[{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prabhsimranjot Singh","raw_affiliation_strings":["Dana-Farber Brigham and Women's Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Brigham and Women's Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027475156","display_name":"B\u00e9len Fraile","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Belen Fraile","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084009521","display_name":"Shobana Muthulingam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shobana Muthulingam","raw_affiliation_strings":["Dana-Farber Cancer Institute, Bostob, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Bostob, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002989987","display_name":"Andrew J. Wagner","orcid":"https://orcid.org/0000-0002-4384-9448","observed_orcids":["https://orcid.org/0000-0002-4384-9448"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew J. Wagner","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037393862","display_name":"Joseph O. Jacobson","orcid":"https://orcid.org/0000-0001-8634-5891","observed_orcids":["https://orcid.org/0000-0001-8634-5891"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph O. Jacobson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078193406","display_name":"Nicole R. LeBoeuf","orcid":"https://orcid.org/0000-0002-8264-834X","observed_orcids":["https://orcid.org/0000-0002-8264-834X"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole R. LeBoeuf","raw_affiliation_strings":["Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA;","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080783554","display_name":"Osama E. Rahma","orcid":"https://orcid.org/0000-0001-7302-5805","observed_orcids":["https://orcid.org/0000-0001-7302-5805"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Osama E. Rahma","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"30_suppl","first_page":"326","last_page":"326"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8989999890327454},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.996999979019165},{"id":"https://openalex.org/keywords/immunotherapy-toxicity-management","display_name":"immunotherapy toxicity management","score":0.7749999761581421},{"id":"https://openalex.org/keywords/emergency-department-visits","display_name":"emergency department visits","score":0.7070000171661377},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.9589999914169312},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8700000047683716},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9229999780654907},{"id":"https://openalex.org/keywords/natural-language-processing","display_name":"natural language processing","score":0.722000002861023},{"id":"https://openalex.org/keywords/hospital-readmission-reduction","display_name":"hospital readmission prevention","score":0.382999986410141}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.928189754486084},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8130735158920288},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8116205930709839},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.774982213973999},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.7164363861083984},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.7021245360374451},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6065630912780762},{"id":"https://openalex.org/C2779328685","wikidata":"https://www.wikidata.org/wiki/Q1475557","display_name":"Patient safety","level":3,"score":0.4679861068725586},{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.4241529703140259},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42165741324424744},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34847667813301086},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3392474055290222},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.23021897673606873},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2106133997440338},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.30_suppl.326","doi":"https://doi.org/10.1200/jco.2018.36.30_suppl.326","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.30_suppl.326","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947001961","https://openalex.org/W3028731517","https://openalex.org/W4388203472","https://openalex.org/W4412855719","https://openalex.org/W4387962233","https://openalex.org/W3029829959","https://openalex.org/W4396520609","https://openalex.org/W7139090389","https://openalex.org/W4403502220","https://openalex.org/W4410875922"],"abstract_inverted_index":{"326":[0],"Background:":[1],"The":[2,101,266,277],"immune":[3],"checkpoint":[4],"inhibitors":[5],"(ICIs)":[6],"confer":[7],"a":[8,32,60,88,164,185,273],"risk":[9],"of":[10,39,47,90,95,106,128,168,182,187,280,306],"unique":[11,189,247,257],"inflammatory":[12],"immune-related":[13],"adverse":[14,23],"events":[15,24,249,259],"(irAEs),":[16],"which":[17,166],"are":[18],"highly":[19],"distinct":[20],"from":[21,75,148,245],"the":[22,45,76,93,149,180,239,251,261,304],"historically":[25],"observed":[26],"with":[27,73,126,198,202,206,210,216,220,225],"cytotoxic":[28],"therapy.":[29],"To":[30],"develop":[31],"strategy":[33],"for":[34,78,92,275,313,315,322],"easier":[35],"identification":[36],"and":[37,50,81,84,112,130,132,154,175,223,230,296,302,324,329],"mitigation":[38],"irAEs,":[40,316],"we":[41],"sought":[42],"to":[43,86,144,162,172,255,271,289],"understand":[44],"frequency":[46],"ED":[48,123,228,294],"visits":[49,229,295],"hospitalizations":[51,297],"in":[52,250,260],"90":[53,234],"days":[54,235],"following":[55],"ICI":[56,137],"start":[57],"by":[58,115],"implementing":[59],"rapid":[61,98],"learning":[62,99],"system":[63,156],"(RLS).":[64],"Methods:":[65],"We":[66],"convened":[67],"an":[68,96,104,169,319,327],"Immunotherapy":[69],"Toxicities":[70],"Management":[71],"Committee":[72,102],"representatives":[74],"Center":[77],"Immuno-Oncology,":[79],"Quality":[80],"Patient":[82],"Safety,":[83],"Informatics":[85],"draft":[87],"series":[89],"recommendations":[91],"development":[94],"irAE":[97],"system.":[100],"requested":[103],"audit":[105],"all":[107],"irAEs":[108,292],"between":[109,291],"June":[110],"2015":[111],"April":[113],"2018":[114],"drug,":[116],"event":[117],"type":[118],"(clinical":[119],"diagnosis),":[120],"outcomes":[121],"(including":[122],"visits,":[124],"hospitalization":[125,231],"length":[127],"stay,":[129],"death),":[131],"time-frame":[133],"(days":[134],"since":[135],"beginning":[136],"course).":[138],"An":[139],"automated":[140,170],"pipeline":[141],"was":[142,160],"created":[143],"merge":[145],"structured":[146],"data":[147,159],"Electronic":[150],"Health":[151],"Record":[152],"(Epic)":[153],"billing":[155],"(EPSi).":[157],"This":[158],"used":[161],"design":[163],"tool":[165,270,282],"consisted":[167],"dashboard":[171,267],"monitor":[173],"patient":[174,248,258],"enable":[176],"interventions.":[177],"Results:":[178],"Over":[179],"course":[181],"3":[183],"years,":[184],"total":[186],"2,020":[188],"patients":[190],"receiving":[191],"ICIs":[192],"were":[193,196,236],"seen.":[194],"918":[195],"treated":[197],"Pembrolizumab":[199,252],"(45.4%),":[200],"768":[201],"Nivolumab":[203,211],"(38.0%),":[204],"234":[205],"Atezolizumab":[207,262],"(11.6%),":[208],"111":[209],"&":[212],"Ipilmumab":[213],"(5.6%),":[214],"68":[215],"Ipilimumab":[217],"(3.4%),":[218],"9":[219,224],"Durvalumab":[221],"(0.4%),":[222],"Avelumab":[226],"(0.4%).":[227],"rates":[232],"over":[233],"similar":[237],"among":[238],"three":[240],"most":[241],"prescribed":[242],"therapies,":[243],"ranging":[244],"332":[246],"Cohort":[253],"(36.1%)":[254],"96":[256],"cohort":[263],"(41.0%).":[264],"Conclusions:":[265],"is":[268,283],"effective":[269],"build":[272],"RLS":[274],"irAEs.":[276],"immediate":[278],"output":[279],"this":[281],"using":[284],"natural":[285],"language":[286],"processing":[287],"(NLP)":[288],"distinguish":[290],"related":[293],"or":[298],"regular":[299],"disease":[300],"progression,":[301],"measure":[303],"impact":[305],"interventions":[307],"including":[308],"(a)":[309],"developing":[310,326],"standardized":[311],"algorithms":[312],"monitoring":[314],"(b)":[317],"designing":[318],"educational":[320],"program":[321],"providers,":[323],"(c)":[325],"inpatient":[328],"outpatient":[330],"immunotherapy":[331],"toxicity":[332],"management":[333],"service.":[334]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2018-10-05T00:00:00"}